Biotechnology

ORLive Program Discusses Ideal Procedure for High-Risk Cardiac Patients

In the past, total arch replacement was considered to be one of the most risky cardiac procedures because the patient had to be put on a heart-lung machine and blood flow to the head and body were temporarily stopped after the patient had been ...

16 hours ago

Aoxing Pharmaceutical Company Announces Second Quarter Fiscal 2012 Financial and Operational Results

Aoxing Pharmaceutical Company, Inc. , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and ...

16 hours ago

Amgen Names Michael Severino, M.D., Senior Vice President, Global Development and Corporate Chief Medical Officer

17 hours ago

AMPAC Fine Chemicals Continues to Invest in Quality Systems

AMPAC Fine Chemicals LLC , a wholly owned subsidiary of American Pacific Corporation , reports that it has joined Rx-360 as an active member. Rx-360 is a pharmaceutical and biotech industry consortium that was founded by industry leaders to enhance ...

18 hours ago

American Diabetes Association Applauds Funding for National Diabetes Prevention Program

The American Diabetes Association applauds the U.S. Department of Health and Human Services for providing $10 million in Fiscal Year 2012 funding for the National Diabetes Prevention Program from the Prevention and Public Health Fund.

18 hours ago

Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations

Laureate Biopharmaceutical Services, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of Les Mintzmyer as Vice President, Operations. He will be responsible for continuing ...

20 hours ago

Ablynx Strengthens Management Team With the Appointment of Dr Andreas Menrad as Chief Scientific Officer

Ablynx , today announced that it has appointed Dr Andreas Menrad as its Chief Scientific Officer.

21 hours ago

Neuralstem Announces Closing of $5.2-Million Registered Direct Offering

Neuralstem, Inc. announced today that it has closed on its previously announced registered direct placement of 5,200,000 shares of common stock at a price of $1.00 per share, and 5,200,000 warrants each with an exercise price of $1.02 per share and ...

21 hours ago

Organovo Announces $6.5 Million Private Placement to Advance 3D Bioprinting for Medical Applications

Organovo Holdings, Inc. today announced the successful completion of a merger on February 8, 2012, with Organovo, Inc. , a company focused on the development of three-dimensional bioprinting technology for research and medical applications. ...

21 hours ago

Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial

21 hours ago

MaRS Client Infonaut Signs Contract with University Health Network to Test Disease Surveillance System, Hospital Watch L

TORONTO, Feb. 14, 2012 /PRNewswire/ - Health technology company Infonaut , a MaRS client, announced it has signed a contract with the University Health Network to test its real-time disease surveillance system, Hospital Watch Live, at the Toronto ...

23 hours ago

Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today that the company completed its $4.1 million Series A angel-led financing. Cherrystone Angels ...

23 hours ago

Cytonet Trials Aim to Better Assess Severity of Urea Cycle Disorders Using New Assay for Urea Production

International biotechnology firm Cytonet has launched a new clinical trial in Germany to compare the urea cycle activity of pediatric patients suffering from urea cycle disorders to normal healthy children using an innovative assay to measure urea ...

23 hours ago

Elsevier Introduces Expert Discovery Application for SciVerse Hub

24 hours ago

UBM Live Appoints Jim Buckley as Informex Brand Director

24 hours ago

Atossa Genetics, Inc. Announces Filing of S-1 Registration Statement

Atossa Genetics, Inc., a privately-held health care company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ...

24 hours ago

Frost & Sullivan Launches the U.S. Drug Delivery: Voice of the Customer 2012 Feasibility Survey

The viewpoints and needs of consumers and prescribers is of the utmost importance when determining the viability of any undertaking in the pharmaceutical space. With this in mind, Frost & Sullivan embarks on a mission to address issues ...

24 hours ago

Interstate Specialty Introduces Speed to Market Program for Die Cut Parts

Interstate Specialty Products, Inc. is introducing a new speed-to-market prototype program that delivers precision digital dieless cut parts produced perfectly to help OEMs meet fast product development cycles.

24 hours ago

JumpStart Invests $250,000 in Milo Biotechnology

Milo Biotechnology will receive $250,000 from JumpStart Inc., a nonprofit investing intensive business assistance and some capital into early stage Northeast Ohio-based tech companies. A clinical stage startup developing a therapy to increase ...

24 hours ago

VistaGen Updates Pipeline of Stem Cell Technology-Based Drug Rescue Candidates

VistaGen Therapeutics, Inc. , a biotechnology company applying stem cell technology for drug rescue and cell therapy, has identified its initial Top 10 drug rescue candidates and plans to launch two formal drug rescue programs by the end of next ...

24 hours ago

21 - 40 of 48581 Stories
<< < Next 20 Biotechnology > >>

NEWS

WIRES

OTHER

Biotechnology